BBOT Advances Triple KRAS-PI3Kα Pipeline with Dual Combination Dosing, Reports $344M Cash Runway into 2028
核心洞察
BridgeBio Oncology Therapeutics (搜索) reported meaningful progress across all three clinical programs targeting RAS-pathway malignancies, including initiation of BBO-11818 in combination with cetuximab and with BBO-10203.
Preclinical data presented at AACR demonstrated BBO-11818 potency in KRAS G12D (搜索)/V models and BBO-10203 efficacy with HER2 inhibitors tucatinib and trastuzumab in HER2amp tumors.
R&D expenses rose to $49.2 million in Q2 2026 from $27.4 million in Q2 2025, reflecting increased clinical trial and manufacturing activities across the pipeline.
BridgeBio Oncology Therapeutics (搜索), Inc. (BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, reported its second quarter 2026 financial results and corporate progress on August 11, 2026, highlighting significant advancement across its three clinical programs and a strengthened financial position.
The South San Francisco-based company is advancing a portfolio of orally bioavailable small molecule RAS-pathway inhibitors designed to target the most mutated driver oncogene in human cancer. The pipeline includes BBO-8520, a direct inhibitor of both ON and OFF states of KRAS G12C (搜索); BBO-11818, a pan-KRAS inhibitor targeting mutant KRAS G12D (搜索)/V in both states; and BBO-10203, a novel mechanism agent that blocks the physical interaction between RAS and PI3Kα (搜索) to inhibit RAS-driven PI3Kα-AKT signaling.
"During the second quarter, we made meaningful progress in patient enrollment in our monotherapy and combination cohorts across each of our three clinical programs," said Pedro J. Beltran, Ph.D., Chief Executive Officer of BBOT. "Differentiated patient benefit in oncology is driven by optimal target coverage and the ability to combine with standard-of-care regimens. Therefore, we continue to focus heavily on advancing our combination development strategies."
BBO-8520: Targeting KRAS G12C (搜索) in NSCLC
BBO-8520, an orally bioavailable small molecule direct inhibitor of both ON and OFF states of KRAS G12C (搜索), continued enrollment in combination with pembrolizumab in patients with non-small cell lung cancer (搜索) (NSCLC) carrying the KRAS G12C mutation. During the quarter, BBOT also initiated dosing of BBO-8520 in combination with BBO-10203 in patients with G12C NSCLC, marking the first internal combination pairing of a KRAS inhibitor with the company's PI3Kα (搜索) pathway disruptor.
BBO-11818: Pan-KRAS Inhibition Expands Combination Reach
BBO-11818, an orally bioavailable pan-KRAS inhibitor targeting mutant KRAS in both ON and OFF states, continued monotherapy enrollment across multiple dose levels. The company initiated dosing of BBO-11818 in combination with cetuximab during the quarter, and subsequent to the quarter's end, initiated dosing of BBO-11818 in combination with BBO-10203.
At the American Association for Cancer Research (AACR) annual meeting, BBOT presented preclinical data demonstrating the potency of BBO-11818 in KRAS G12D (搜索) and KRAS G12V (搜索) cell line-derived xenograft (CDX) models. The data also highlighted a potent combination effect with cetuximab or BBO-10203, and complete tumor regressions mediated through adaptive immunity when combined with anti-PD-1 antibodies.
BBO-10203: Novel RAS-PI3Kα (搜索) Interaction Blocker
BBO-10203, designed to block the physical interaction between RAS and PI3Kα (搜索), continued enrollment in hormone receptor-positive breast cancer (搜索) (HR+ BC), HER2-positive/HER2-low breast cancer (HER2+/HR- BC), and colorectal cancer (搜索) (CRC) combination cohorts. Preclinical data presented at AACR showed that BBO-10203 demonstrated strong in vivo combination effects with HER2 inhibitors tucatinib or trastuzumab in HER2-amplified (HER2amp) tumor models.
Financial Position and Outlook
As of June 30, 2026, BBOT reported cash, cash equivalents, and marketable securities totaling $344.1 million, which the company expects will provide a cash runway into 2028.
Research and development expenses for the second quarter of 2026 were $49.2 million, compared to $27.4 million for the same period in 2025. The increase was primarily driven by higher clinical trial expenses and manufacturing costs for BBO-8520, BBO-11818, and BBO-10203. General and administrative expenses rose to $11.0 million from $2.7 million in the prior-year quarter, reflecting the initiation of BBOT's standalone operations, its de-SPAC transaction, and one-time severance costs for former executives.
Net loss for the second quarter of 2026 was $56.5 million, compared to $28.4 million in the second quarter of 2025. For the six months ended June 30, 2026, net loss totaled $98.6 million versus $50.5 million in the prior-year period.
Beltran emphasized the strategic positioning of the company's wholly-owned portfolio: "Our wholly-owned portfolio is uniquely positioned to enable concurrent suppression of the MAPK and PI3Kα (搜索) pathways through internal combination strategies of each of our KRAS inhibitors with BBO-10203. We are excited to have both combinations already underway in patients."
With multiple near-term clinical milestones expected across all programs in the second half of 2026 and a cash runway extending into 2028, BBOT appears well-capitalized to execute on its strategy of expanding treatment options for patients with mutant KRAS-driven cancers.